Work

Multicenter characterization of enterocolitis associated with BCMA-directed CAR T cell therapy

Year: 2026
Type: article
Study design: Observational Study
Abstract: Immune effector cell-associated enterocolitis (IEC-EC) is a delayed toxicity of ciltacabtagene autoleucel. The US Multiple Myeloma Immunotherapy Consortium retrospectively adjudicated 54 suspected cases from 8 institutions: 41 were IEC-EC (31 confirmed by anti-camelid variable heavy-chain immunohistochemistry, 10 probable). Through September 2025, cumulative incidence was 3.0% (39 of 1,308 ciltacabtagene autoleucel recipients; 95% CI 2.1–4.1%); 12-month competing-risk incidence was 3.0% (95% CI 2.1–4.1%). Median symptom onset was 75 days after infusion. Grade ≥3 diarrhea occurred in 85% (34 of 40 with diarrhea); 73% (30 of 41) required parenteral nutrition. Despite normal upper endoscopy in 41% (9 of 22), duodenal biopsies showed villous blunting, apoptotic bodies and a dense cytotoxic T cell infiltrate, CD4 + in 61% (19 of 31), CD8 + in 26% (8 of 31) and mixed in 13% (4 of 31). A dominant T cell clone was detected in 76% (13 of 17 tested). Delayed neurotoxicity co-occurred in 41% (17 of 41). At last follow-up, 32% (13 of 41) resolved, 27% (11 of 41) had ongoing symptoms and 41% (17 of 41) died with active IEC-EC. Combined biologic and T cell-directed therapy yielded the highest resolution (55%, 6 of 11) in small subgroups. IEC-EC is potentially fatal and requires systematic evaluation and early directed therapy.
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: hybrid
Estimated APC paid: $12,690
OpenAlex ID: W7236713982
FWCI:
Cites: 19
Cited by:
Related to: 10